NASDAQ NMS - GLOBAL MARKET · DSGN
+1.39% · +$0.1600 · Vol 356.6K
Market closed · last close 4:00 PM ET · price as of 16:01:29 ET
Design Therapeutics Inc

Design Therapeutics Inc

Biotechnology
$11.65
Card
Relationship Map

Follow $DSGN

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $DSGN by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
DSGN
Design Therapeutics Inc
Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

55/ 100
Veridion Score
Middle range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5 of 6 factors measured · Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is DSGN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading DSGN catalysts
About Design Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
55
Country
US

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$11.47
Day high
$11.92
Day low
$11.40
Previous close
$11.49
52W high
$15.94
-26.91% from high
52W low
$5.53
59% of range
Market cap
$719.1M
EPS
$-1.1804
Beta
0.72
Shares out
62.6M
Volume
356.6K
0.50× rel vol
Avg volume
707.2K
VWAP
$11.68
Price history computed in-house
1W
-5.59%
1M
-21.28%
3M
-23.30%
1Y
+72.59%
YTD
+24.20%
SMA 50 $13.77 · below
SMA 200 $12.08 · below
52W position 59%

DSGN overview

Veridion Score
55
Registered · 2026-10-09
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around DSGN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading DSGN Form 4 filings
Public disclosures

Congress activity in DSGN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

DSGN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DSGN in this window.
Lobbying spend

DSGN lobbying filings, year to date.

Registered lobbying filings matched to Design Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DSGN in this window.
Loading news for DSGN
Analyst ratings
Sovereign unlock shows live analyst consensus for DSGN.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.